Viewing data from:

ONDANSETRON

ANDA

ONDANSETRON | A209389 | IPCA LABORATORIES LTD

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.1710

per ea

Lowest NADAC/Unit

$0.1277

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
83980001313ONDANSETRON ODT 8 MG TABLET	$0.1710	EA	Generic	—	2026-06-17
83980001213ONDANSETRON ODT 4 MG TABLET	$0.1277	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain10 active DMFs3 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

TEVA PHARMACEUTICAL INDUSTRIES LTDONDANSETRON HCL DIHYDRATE

DMF 156422001

CIPLA LTDONDANSETRON HCL USP

DMF 157242001

CAMBREX CHARLES CITY INCONDANSETRON HCL

DMF 157522001

INKE SAONDANSETRON BASE

DMF 161722002

DR REDDYS LABORATORIES LTDONDANSETRON

DMF 163202003

TAPI NL BVONDANSETRON BASE

DMF 166442003

SUN PHARMACEUTICAL INDUSTRIES LTDONDANSETRON USP

DMF 179802005

HIKAL LTDONDANSETRON USP

DMF 188292005

IPCA LABORATORIES LTDONDANSETRON USP

DMF 237582010

ALIVUS LIFE SCIENCES LTDONDANSETRON USP

DMF 439382026

CHEMSOURCE CORPInactiveONDANSETRON HCL

DMF 157832001

QILU PHARMACEUTICAL CO LTDInactiveONDANSETRON

DMF 197622006

CADILA PHARMACEUTICALS LTDInactiveOndansetron

DMF 210272007

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 4MG

0 patents0 exclusivities▴

TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Oct 30, 2023

No patent or exclusivity listings for this strength.

#002 — 8MG

0 patents0 exclusivities▾

TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Oct 30, 2023